Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.

Patient Profile

Patients with: Histologically or cytologically documented non-small cell lung carcinoma
Advanced disease defined as recurrent stage IV (according to 8th TNM classification) or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemo-radiation therapy for locally advanced disease)
At least one prior platinum-based systemic regimen: Adjuvant or neoadjuvant or definitive platinum-based chemo-radiotherapy treatments are considered as a line of treatment only if completed less than 6 months before enrollment. Maintenance therapy following platinum doublet-based chemotherapy is not considered a separate regimen of therapy.

Where’s this trial being run?

St James’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: ETOP 12-17 ALERT
Number: 16-59
Full Title:

A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC

Principal Investigator: Dr. Sinéad Cuffe
Type: Collaborative
Sponsor:

European Thoracic Oncology Platform (ETOP)

Recruitment Started: Global: June 2018
Ireland: September 2018
Global Recruitment Target: 44
Ireland Recruitment Target: 1-2